Tvardi Therapeutics, Inc. (TVRD) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 1 Buy, 3 Hold.
The consensus price target is $4.50 (low: $4.00, high: $5.00), representing an upside of 29.7% from the current price $3.47.
Analysts estimate Earnings Per Share (EPS) of $-45.24 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-46.59 vs est $-45.24 (missed -3%). 2025: actual $-2.46 vs est $-2.23 (missed -10.3%). Analyst accuracy: 94%.
TVRD Stock — 12-Month Price Forecast
$4.50
▲ +29.68% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Tvardi Therapeutics, Inc., the average price target is $4.50, with a high forecast of $5.00, and a low forecast of $4.00.
The average price target represents a +29.68% change from the last price of $3.47.
Highest Price Target
$5.00
Average Price Target
$4.50
Lowest Price Target
$4.00
TVRD Analyst Ratings
Hold
Based on 4 analysts giving stock ratings to Tvardi Therapeutics, Inc. in the past 3 months
EPS Estimates — TVRD
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$46.59
vs Est –$45.24
▼ 2.9% off
2025
Actual –$2.46
vs Est –$2.23
▼ 9.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TVRD
100%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.007B
vs Est $0.007B
▼ 0.1% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
